December 6, 2018 8:24am
Indications: The iShares Nasdaq Biotechnology (IBB -1.36%), the SPDR S&P Biotech ETF (XBI -1.5%), the iShares Russell 2000 (IWM -1.3%), the Health Care Select Sector SPDR ETF (XLV -1.06) are DOWNSLIDING
News: Intellia Therapeutics (NTLA) expands existing cell therapy collaboration with Novartis, to include the ex vivo development of innovative cell therapies using certain ocular stem cells. Biogen (BIIB) exercised its option to obtain from Ionis Pharmaceuticals (IONS) a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB067 (IONIS-SOD1RX), an investigational treatment for amyotrophic lateral sclerosis (ALS) with superoxide dismutase 1 (SOD1) mutations.
Pre-open indications: a sector bounce is needed as I rank 14 OVERSOLD to BUYs; maybe not today; yet it’s coming!
I answer one question, in which company should investors put, keep and commit their money!
Members only. Please login.